Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.67 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.67 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL859799 | 1.00 | P2RY2 (0.68) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL28286418 | 1.00 | P2RY2 (0.68) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL17934719 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL14669262 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL11217191 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL284602 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL6115643 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL207204 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL2681941 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL16189 | 0.99 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105213318-A | Comprise the compositions of oil droplet | SIGMOID PHARMA LTD | 2016-01-06 | — | — | CN | claimed |
| CN-113784706-B | Multi-layered pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and B vitamins, their preparation and use | 菲尔若国际公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-113784706-A | Multi-layered pharmaceutical or nutraceutical solid dosage form comprising pyrimidine and/or purine derivatives and B vitamins, preparation and use thereof | 菲尔若国际公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-107737339-B | Calcium phosphate-biomolecule composite material and preparation method thereof | 中国科学院上海硅酸盐研究所 | 2021-06-15 | — | — | CN | disclosed |
| CN-109071579-B | Method for producing monomer for single-stranded nucleic acid molecule | 住友化学株式会社 | 2021-05-14 | — | — | CN | disclosed |
| EP-3450439-B1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | SUMITOMO CHEMICAL CO (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-10308672-B2 | Method for producing monomer for single-stranded nucleic acid molecule | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190100540-A1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-04 | — | — | US | disclosed |
| CN-106632531-B | A kind of preparation method of α -2,3 hydroxyl acetylsalicylic acid lactulose | 河南科技学院 | 2019-02-22 | — | — | CN | disclosed |
| EP-3268027-A1 | HEPCIDIN ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2018-01-17 | — | — | EP | disclosed |
| EP-2503997-A1 | INHIBITORS OF THE PP1/GADD34 COMPLEX FOR THE TREATMENT OF A CONDITION REQUIRING AN IMMUNOSUPPRESSIVE ACTIVITY | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2012-10-03 | — | — | EP | disclosed |
| CN-102573802-A | Immunomodulatory compositions comprising a polymer matrix and an oil phase | SIGMOID PHARMA LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-102470106-A | Composition comprising oil droplets | SIGMOID PHARMA LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2432455-A2 | COMPOSITION COMPRISING OIL DROPS | Sigmoid Pharma Limited (IE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011098516-A1 | IMPROVED COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION | IMMUNICUM AB (SE) | 2011-08-18 | — | — | WO | disclosed |
| EP-2343982-A2 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | Chiasma Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011061340-A1 | INHIBITORS OF THE PP1/GADD34 COMPLEX FOR THE TREATMENT OF A CONDITION REQUIRING AN IMMUNOSUPPRESSIVE ACTIVITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010133609-A2 | COMPOSITION COMPRISING OIL DROPS | SIGMOID PHARMA LIMITED (IE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010032140-A2 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | CHIASMA INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2007139821-A2 | METHODS OF USING LRR SUPERFAMILY GENES AND PROTEINS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308672-B2 | Method for producing monomer for single-stranded nucleic acid molecule | DNA2, POLM, POLRMT | P2RY2 1554/4885LMNA 620/4885THRB 4064/4885 |
| US-20190100540-A1 | METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE | DNA2, POLM, POLRMT | P2RY2 1554/4885LMNA 620/4885THRB 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.